Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results